Fig. 1: TRIO-US B07 clinical trial participants. | Nature Communications

Fig. 1: TRIO-US B07 clinical trial participants.

From: Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Fig. 1: TRIO-US B07 clinical trial participants.

130 participants were enrolled across three treatment arms. All participants received docetaxel plus carboplatin (TC) every 3 weeks. In addition, participants in Arm 1 received trastuzumab (TCH), Arm 2 received lapatinib (TCL), and Arm 3 received both trastuzumab and lapatinib (TCHL). Two participants withdrew from the study prior to starting any treatment, leaving 128 participants remaining in the intent to treat (ITT) population. Of 128 participants, 25 came off study treatment prior to surgery (10 in Arm 2, 15 Arm 3), leaving 103 participants included in the evaluable analysis.

Back to article page